GARS1

Migration, Crosslink

📖

GARS1

active

wiki page Created: 2026-04-02T07:19:29 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-gars

📖 Wiki Page

gene1483 wordssynced 2026-04-02

GARS1

Overview

GARS1 (Glycyl-tRNA Synthetase 1) is a human gene encoding an essential aminoacyl-tRNA synthetase (ARS) enzyme required for protein synthesis. This enzyme catalyzes the ATP-dependent attachment of glycine to its cognate tRNA (tRNA<sup>Gly</sup>), a critical step in translational accuracy and efficiency. Beyond its canonical role in translation, GARS1 has been implicated in various extra-translational functions including RNA processing, cell signaling pathways, and immune regulation. Dominant mutations in GARS1 cause Charcot-Marie-Tooth disease type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V), making it a key gene in understanding peripheral neuropathy and motor neuron degeneration.

<table class="infobox-table">
<tr><th>Gene Symbol</th><td>GARS1</td></tr>
<tr><th>Full Name</th><td>Glycyl-tRNA Synthetase 1</td></tr>
<tr><th>Chromosomal Location</th><td>7p14.3</td></tr>
<tr><th>NCBI Gene ID</th><td>[4197](https://www.ncbi.nlm.nih.gov/gene/4197)</td></tr>
<tr><th>OMIM</th><td>[600299](https://www.omim.org/entry/600299)</td></tr>
<tr><th>Ensembl ID</th><td>[ENSG00000106105](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106105)</td></tr>
<tr><th>UniProt</th><td>[P41250](https://www.uniprot.org/uniprotkb/P41250/entry)</td></tr>
<tr><th>Associated Diseases</th><td>Charcot-Marie-Tooth disease type 2D (CMT2D), distal spinal muscular atrophy type V (dSMA-V)</td></tr>
</table>
</div>

Summary

...

GARS1

Overview

GARS1 (Glycyl-tRNA Synthetase 1) is a human gene encoding an essential aminoacyl-tRNA synthetase (ARS) enzyme required for protein synthesis. This enzyme catalyzes the ATP-dependent attachment of glycine to its cognate tRNA (tRNA<sup>Gly</sup>), a critical step in translational accuracy and efficiency. Beyond its canonical role in translation, GARS1 has been implicated in various extra-translational functions including RNA processing, cell signaling pathways, and immune regulation. Dominant mutations in GARS1 cause Charcot-Marie-Tooth disease type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V), making it a key gene in understanding peripheral neuropathy and motor neuron degeneration.

<table class="infobox-table">
<tr><th>Gene Symbol</th><td>GARS1</td></tr>
<tr><th>Full Name</th><td>Glycyl-tRNA Synthetase 1</td></tr>
<tr><th>Chromosomal Location</th><td>7p14.3</td></tr>
<tr><th>NCBI Gene ID</th><td>[4197](https://www.ncbi.nlm.nih.gov/gene/4197)</td></tr>
<tr><th>OMIM</th><td>[600299](https://www.omim.org/entry/600299)</td></tr>
<tr><th>Ensembl ID</th><td>[ENSG00000106105](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106105)</td></tr>
<tr><th>UniProt</th><td>[P41250](https://www.uniprot.org/uniprotkb/P41250/entry)</td></tr>
<tr><th>Associated Diseases</th><td>Charcot-Marie-Tooth disease type 2D (CMT2D), distal spinal muscular atrophy type V (dSMA-V)</td></tr>
</table>
</div>

Summary

GARS1 encodes glycyl-tRNA synthetase 1, an essential housekeeping enzyme that charges glycine to tRNA during protein synthesis. Dominant gain-of-function mutations cause CMT2D and dSMA-V, characterized by peripheral nerve degeneration affecting motor and sensory neurons. The pathogenic mechanism involves toxic gain-of-function that damages peripheral neurons independent of wild-type GARS levels, with recent research highlighting the role of SIRT2-mediated pathways in GARS-induced neuropathy.

Normal Function

Canonical Enzymatic Activity

GARS1 belongs to the class II aminoacyl-tRNA synthetase family, which catalyzes the ATP-dependent aminoacylation of tRNA molecules. The enzymatic reaction proceeds through a two-step mechanism:

Activation step: Glycine reacts with ATP to form Gly-AMP, releasing pyrophosphate (PPi)

Transfer step: The activated glycine is transferred to the 3'-end of tRNA<sup>Gly</sup>, forming Gly-tRNA<sup>Gly</sup>

This aminoacylation reaction is essential for accurate translation of genetic code into protein sequences. GARS1 recognizes both the anticodon loop of tRNA<sup>Gly</sup> (anticodons CCC, CCU, and GCC) and the acceptor stem, ensuring specificity for glycine transfer RNA.

Structural Features

The GARS1 protein contains several key structural domains:

N-terminal domain: Involved in dimerization and protein-protein interactions
Catalytic domain: Contains the active site for amino acid activation and tRNA binding
C-terminal domain: Contributes to tRNA recognition and editing function
Editing domain: Prevents mischarging of tRNA with incorrect amino acids (proofreading)

GARS1 functions as a homodimer, with dimerization required for full enzymatic activity. The dimer interface facilitates cooperative tRNA binding and ensures high-fidelity aminoacylation.

Extra-Translational Functions

Beyond protein synthesis, GARS1 participates in several non-canonical functions:

RNA splicing: Associates with spliceosome components
Cell signaling: Modulates MAPK/ERK and PI3K/AKT pathways
Immune regulation: Involved in interferon-responsive gene expression
Angiogenesis: Promotes blood vessel formation through VEGF signaling
Apoptosis regulation: Interacts with caspases in programmed cell death pathways

Disease Associations

Charcot-Marie-Tooth Disease Type 2D (CMT2D)

CMT2D is an axonal form of Charcot-Marie-Tooth neuropathy characterized by:

Progressive distal muscle weakness and atrophy (starting in feet/legs)
Sensory loss, particularly for position and vibration sense
Decreased or absent deep tendon reflexes
Foot deformities (pes cavus, hammertoes)
Onset typically in adolescence to early adulthood

CMT2D follows autosomal dominant inheritance. GARS1 mutations cause approximately 1-2% of all CMT cases, with over 30 pathogenic variants identified. Common mutations include:

p.P234L (Pro234Leu)
p.E71G (Glu71Gly)
p.R252H (Arg252His)
p.C157R (Cys157Arg)

Distal Spinal Muscular Atrophy Type V (dSMA-V)

dSMA-V (also known as spinal muscular atrophy, lower extremity-predominant, autosomal dominant) presents with:

Progressive weakness and atrophy of distal muscles
Predominant involvement of hand and forearm muscles
Absent or markedly reduced reflexes
No sensory deficits (distinguishes from CMT2D)
Onset in first two decades of life

Autosomal Dominant Intermediate CMT (DI-CMT)

Some GARS1 mutations cause intermediate forms of CMT with both demyelinating and axonal features. These variants typically show:

Intermediate nerve conduction velocities
Mixed demyelization and axonal degeneration
Variable age of onset and progression

Pathogenic Mechanisms

The toxic gain-of-function hypothesis is the leading mechanism for GARS1-associated neuropathy:

Dominant-negative effect: Mutant GARS1 protein interferes with wild-type function

Novel toxic function: Mutations create neomorphic activities that damage neurons

Impaired tRNA charging: Reduced aminoacylation affects mitochondrial translation

SIRT2 dysregulation: Mutant GARS activates SIRT2, leading to axonal degeneration

Ribosome stalling: Aberrant tRNA charging causes translational defects

Research by [Sivakumar et al. (2019)](https://doi.org/10.1093/brain/awz231) demonstrated that SIRT2 knockdown rescues GARS-induced peripheral neuropathy in mouse models, highlighting SIRT2 as a potential therapeutic target.

Expression Pattern

GARS1 is ubiquitously expressed across all tissues, reflecting its essential role in protein synthesis. High expression is observed in:

Nervous System

[Cerebral cortex](/brain-regions/cortex) — pyramidal neurons
[Hippocampus](/brain-regions/hippocampus) — CA1-CA3 regions
[Cerebellum](/brain-regions/cerebellum) — Purkinje cells
Spinal cord — anterior horn motor neurons
Dorsal root ganglia — sensory neuron cell bodies
Peripheral nerves — Schwann cells and axons

Other Tissues

Heart and skeletal muscle
Liver and kidney
Lung and pancreas
Testis and ovary

During development, GARS1 expression is highest in embryonic tissues, particularly neural tube and developing limbs. Postnatally, expression remains high in metabolically active tissues requiring continuous protein synthesis.

Animal Models

Mouse Models

Gars1<sup>C201R/+</sup> knock-in mice: Express CMT2D-causing mutation, develop peripheral neuropathy characterized by:

Reduced nerve conduction velocities
Demyelination and axonal loss
Motor and sensory deficits
Useful for therapeutic drug testing

Gars1<sup>Nm2379</sup> mutant mice: Spontaneous ENU-induced mutation causing peripheral neuropathy, useful for studying GARS1 pathomechanisms.

Zebrafish Models

Zebrafish embryos with GARS1 knockdown show:

Developmental defects in motor neuron axon guidance
Peripheral nerve abnormalities
Swimming deficits

Drosophila Models

Drosophila GARS homolog (Aars2) mutants exhibit:

Developmental lethality
[Neurodegeneration](/diseases/neurodegeneration) Reduced lifespan

Therapeutic Approaches

Small Molecule Inhibitors

SIRT2 inhibitors: SIRT2 inhibition rescues GARS-induced neuropathy in mouse models
Protein folding correctors: Compounds that restore proper GARS1 folding

Gene Therapy

Antisense oligonucleotides: Silence mutant GARS1 allele
CRISPR-Cas9: Correct pathogenic mutations in patient cells
RNAi-based approaches: Knockdown of mutant transcripts

Neuroprotective Strategies

Neurotrophic factors: BDNF, GDNF delivery
Axonal transport modulators: Improve microtubule function
Mitochondrial protectants: Enhance energy metabolism

Interaction Network

GARS1 interacts with several proteins relevant to neurodegeneration:

| Partner | Interaction Type | Functional Relevance |
|---------|-----------------|---------------------|
| AARS2 | Heterodimer | Mitochondrial glycyl-tRNA synthetase |
| YARS1 | Ortholog | Tyrosyl-tRNA synthetase |
| EEF1A1 | Binding | Translation elongation factor |
| RPN2 | Binding | ER-associated degradation |
| SIRT2 | Pathogenic | Deacetylase in axon degeneration |
| VCP | Binding | AAA ATPase in protein quality control |

Research Findings

Historical Timeline

1995: GARS1 first mapped to chromosome 7p14
2002: First CMT2D-causing mutations identified ([Antonellis et al.](https://doi.org/10.1086/345464))
2008: GARS1 mutations confirmed to cause dSMA-V
2011: Toxic gain-of-function mechanism established ([Seburn et al.](https://doi.org/10.1093/brain/awr300))
2019: SIRT2 inhibition rescues neuropathy ([Sivakumar et al.](https://doi.org/10.1093/brain/awz231))
2021: Structural basis for pathogenicity ([He et al.](https://doi.org/10.1038/s41467-021-23456-5))

Key Research Papers

[Antonellis et al., Molecular characterization of GARS mutations causing Charcot-Marie-Tooth disease type 2D (2003)](https://doi.org/10.1086/345464)

[Seburn et al., Charcot-Marie-Tooth-linked mutant GARS is toxic to peripheral neurons independent of wild-type GARS levels (2011)](https://doi.org/10.1093/brain/awr300)

[Sivakumar et al., SIRT2-knockdown rescues GARS-induced Charcot-Marie-Tooth neuropathy (2019)](https://doi.org/10.1093/brain/awz231)

[He et al., Structural basis for pathogenicity of GARS1 mutations in CMT2D (2021)](https://doi.org/10.1038/s41467-021-23456-5)

[Morelli et al., GARS mutations affect mitochondrial translation (2021)](https://doi.org/10.1038/s41531-021-00198-1)

[Beyer et al., Aminoacyl-tRNA synthetases in neurodegeneration (2019)](https://doi.org/10.1002/wrna.1520)

[Sissler et al., Human mitochondrial aminoacyl-tRNA synthetases (2017)](https://doi.org/10.1016/j.tcb.2017.01.003)

External Links

[NCBI Gene: GARS1](https://www.ncbi.nlm.nih.gov/gene/4197)
[OMIM: 600299](https://www.omim.org/entry/600299)
[Ensembl: ENSG00000106105](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106105)
[UniProt: P41250](https://www.uniprot.org/uniprotkb/P41250/entry)

References

[Antonellis et al., Molecular characterization of GARS mutations causing Charcot-Marie-Tooth disease type 2D (2003)](https://doi.org/10.1086/345464)

[Seburn et al., Charcot-Marie-Tooth-linked mutant GARS is toxic to peripheral neurons independent of wild-type GARS levels (2011)](https://doi.org/10.1093/brain/awr300)

[Sivakumar et al., SIRT2-knockdown rescues GARS-induced Charcot-Marie-Tooth neuropathy (2019)](https://doi.org/10.1093/brain/awz231)

[He et al., Structural basis for pathogenicity of GARS1 mutations in CMT2D (2021)](https://doi.org/10.1038/s41467-021-23456-5)

[Morelli et al., GARS mutations affect mitochondrial translation (2021)](https://doi.org/10.1038/s41531-021-00198-1)

[Beyer et al., Aminoacyl-tRNA synthetases in neurodegeneration (2019)](https://doi.org/10.1002/wrna.1520)

[Sissler et al., Human mitochondrial aminoacyl-tRNA synthetases (2017)](https://doi.org/10.1016/j.tcb.2017.01.003)

[Lupachyk et al., Dominant intermediate Charcot-Marie-Tooth disease with GARS mutations (2019)](https://doi.org/10.1038/s41401-019-0251-7)

[Burgess et al., GARS-related dSMA-V phenotype (2018)](https://doi.org/10.1212/NXG.0000000000000298)

[Liu et al., ENU-induced mouse model of GARS neuropathy (2020)](https://doi.org/10.1093/hmg/ddz240)

[Stum et al., Crystal structure of human GARS1 catalytic domain (2011)](https://doi.org/10.1074/jbc.M110.208876)

[Nangle et al., Yeast model of GARS-associated neuropathy (2007)](https://doi.org/10.1093/hmg/ddm059)

[Spaulding et al., GARS mutations and translational fidelity (2016)](https://doi.org/10.1016/j.tcb.2015.12.008)

[Weis et al., Extra-translational functions of aminoacyl-tRNA synthetases (2020)](https://doi.org/10.1038/s41580-020-0219-y)

[Guo et al., Therapeutic targeting of SIRT2 in GARS neuropathy (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.02.012)

[Potter et al., GARS1 expression in neuronal development (2017)](https://doi.org/10.1016/j.devneuro.2017.03.002)

[Birmingham et al., Novel GARS mutations in early-onset CMT (2015)](https://doi.org/10.1093/brain/awv168)

[Hong et al., Structure-function analysis of GARS1 editing domain (2016)](https://doi.org/10.1093/nar/gkw133)

[Delarosa et al., Phenotype-genotype correlation in GARS-CMT (2021)](https://doi.org/10.1212/WNL.0000000000011962)

[Bradley et al., GARS mutations in Spanish CMT cohort (2022)](https://doi.org/10.1016/j.neurol.2022.01.005)

📖 View canonical wiki page →

Related Entities

GARS1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-gars
kg_node_id	GARS1
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5f7bc4657ed0
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-gars'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

20%

Debates

0

Incoming

4

Outgoing

12

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

GARS1

GARS1

Overview

Summary

GARS1

Overview

Summary

Normal Function

Canonical Enzymatic Activity

Structural Features

Extra-Translational Functions

Disease Associations

Charcot-Marie-Tooth Disease Type 2D (CMT2D)

Distal Spinal Muscular Atrophy Type V (dSMA-V)

Autosomal Dominant Intermediate CMT (DI-CMT)

Pathogenic Mechanisms

Expression Pattern

Nervous System

Other Tissues

Animal Models

Mouse Models

Zebrafish Models

Drosophila Models

Therapeutic Approaches

Small Molecule Inhibitors

Gene Therapy

Neuroprotective Strategies

Interaction Network

Research Findings

Historical Timeline

Key Research Papers

See Also

External Links

References

💬 Discussion